2017
Retinoblastoma: A Sixteen-Year Review of the Presentation, Treatment, and Outcome from a Tertiary Care Institute in Northern India
Singh U, Katoch D, Kaur S, Dogra M, Bansal D, Kapoor R. Retinoblastoma: A Sixteen-Year Review of the Presentation, Treatment, and Outcome from a Tertiary Care Institute in Northern India. Ocular Oncology And Pathology 2017, 4: 23-32. PMID: 29344495, PMCID: PMC5757564, DOI: 10.1159/000477408.Peer-Reviewed Original ResearchRetinoblastoma patientsHistopathological high-risk featuresHistopathological risk factorsHigh-risk featuresTertiary care institutionRate of metastasisDefaulted therapyExtraocular extensionIntraocular diseasePrimary enucleationLocal recurrenceAdvanced diseaseRetrospective reviewPediatric patientsClinical characteristicsPrimary treatmentChemoreductionRisk featuresPatientsRisk factorsTherapy refusalStudy epidemiologyRetinoblastomaEnucleationMetastasis
2016
Risk of metastasis and orbital recurrence in advanced retinoblastoma eyes treated with systemic chemoreduction versus primary enucleation
Berry JL, Kogachi K, Aziz HA, McGovern K, Zolfaghari E, Murphree AL, Jubran R, Kim JW. Risk of metastasis and orbital recurrence in advanced retinoblastoma eyes treated with systemic chemoreduction versus primary enucleation. Pediatric Blood & Cancer 2016, 64: e26270. PMID: 28221729, PMCID: PMC7034314, DOI: 10.1002/pbc.26270.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCombined Modality TherapyEtoposideEye EnucleationFemaleFollow-Up StudiesHumansInfantMaleNeoplasm Recurrence, LocalNeoplasm StagingOrbital NeoplasmsPrognosisRetinal NeoplasmsRetinoblastomaRetrospective StudiesRisk FactorsSalvage TherapyVincristineConceptsPrimary enucleation groupSystemic chemoreductionHigh-risk pathologyMetastatic diseaseOrbital recurrencePrimary enucleationAdvanced retinoblastomaEnucleation groupTreatment failureHigh-risk pathologic featuresChildren's Hospital Los AngelesPrimary outcome measureRisk of metastasisSalvage therapySecondary enucleationRetrospective reviewE retinoblastomaMedian timePathologic featuresRetinoblastoma eyesTreatment modalitiesPoor responseOutcome measuresChemoreductionSubsequent enucleation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply